. 2022 Apr 5;4(1):e000267. doi: 10.1136/bmjno-2022-000267

Table 3.

Outcomes at 3 months by PAS and antiplatelet therapy

Outcomes at 3 months		Total	Events, n (%)	Unadjusted		Adjusted
Outcomes at 3 months		N=2818	Events, n (%)	OR (95% CI)	P value	OR (95% CI)	P value
Recurrence of ischaemic stroke	PAS+DAPT	393	44 (11.2)	Reference	–	Reference	–
	PAS+SAPT	267	19 (7.12)	0.627 (0.366 to 1.073)	0.0887	0.605 (0.352 to 1.039)	0.0687
	Non-PAS+DAPT	1229	51 (4.15)	0.361 (0.241 to 0.541)	<0.0001	0.392 (0.260 to 0.590)	<0.0001
	Non-PAS+SAPT	929	36 (3.88)	0.338 (0.218 to 0.526)	<0.0001	0.363 (0.232 to 0.567)	<0.0001
Composite vascular events	PAS+DAPT	393	47 (11.96)	Reference	–	Reference	–
	PAS+SAPT	267	19 (7.12)	0.586 (0.344 to 0.998)	0.0493	0.563 (0.330 to 0.963)	0.0358
	Non-PAS+DAPT	1229	54 (4.39)	0.358 (0.242 to 0.529)	<0.0001	0.389 (0.262 to 0.579)	<0.0001
	Non-PAS+SAPT	929	37 (3.98)	0.325 (0.211 to 0.500)	<0.0001	0.347 (0.225 to 0.537)	<0.0001
Haemorrhagic stroke	PAS+DAPT	393	1 (0.25)	Reference	–	Reference	–
	PAS+SAPT	267	0	0	0.9980	0	0.9982
	Non-PAS+DAPT	1229	2 (0.16)	0.638 (0.058 to 7.036)	0.7136	0.753 (0.066 to 8.658)	0.8200
	Non-PAS+SAPT	929	0	0	0.9963	0	0.9962
mRS 3–6 (missing 25)*	PAS+DAPT	388	60 (15.46)	Reference	–	Reference	–
	PAS+SAPT	263	33 (12.55)	0.784 (0.497 to 1.239)	0.2975	0.561 (0.337 to 0.937)	0.0270
	Non-PAS+DAPT	1220	106 (8.69)	0.520 (0.370 to 0.731)	0.0002	0.672 (0.465 to 0.972)	0.0350
	Non-PAS+SAPT	912	99 (10.86)	0.666 (0.471 to 0.940)	0.0209	0.731 (0.501 to 1.066)	0.1034

Adjustment for baseline characteristics includes age, sex, history of hypertension, history of diabetes and smoking.

*(mRS) Adjustment for baseline characteristics includes age, sex, history of hypertension, history of diabetes, smoking and NIHSS.

CI, confidence interval; DAPT, dual antiplatelet therapy; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratios; PAS, parent artery stenosis; SAPT, single antiplatelet therapy.